Allocation of Development Costs. (a) Xxxxxxxxx shall be responsible for paying [**] of the Shared Development Costs, and AstraZeneca shall be responsible for paying [**] of the Shared Development Costs.
(b) [**].
Allocation of Development Costs. In the event that the City of Commerce or Seller does not develop the City Public Safety Facility pursuant to Paragraph 3 of this Amendment, and neither of the Buyers proceed with acquisition of the City Public Safety Facility Land, and Seller or the City, directly or through other parties, retains ownership thereof, Seller or the City, as applicable, shall bear (or cause the other party to bear) an allocable cost of those components of development of the overall Property that benefit the City Public Safety Facility Land, such as engineering and architectural costs and studies, infrastructure costs (dry and wet utilities, storm drain facilities, and the like) and the cost of planning and installation of private roads and shared amenities (or cost imposed on the developer for public roads and improvements) in the relation to the square footage of the City Public Safety Facility Land bears to the square footage of the overall Property. Seller and/or the City and Buyers shall cooperate in entering into an agreement that more precisely addresses the foregoing.
Allocation of Development Costs. 13 8.03 Marketing...............................................................14
Allocation of Development Costs. Development Costs for each project shall be allocated between the Parties as follows:
Allocation of Development Costs. Universal Cells shall pay fifty percent (50%) of Development Costs and Adaptimmune shall pay fifty percent (50%) of Development Costs.
Allocation of Development Costs. Subject to Section 2.3 of this Exhibit E, Amgen shall pay [***] of Development Costs and CytomX shall pay [***] of Development Costs.
Allocation of Development Costs. (i) Warner shall pay the first $40,000,000 of the aggregate of the Development Costs for Local/Regional ONYX-015 and Systemic ONYX-015 incurred after the Effective Date pursuant to the applicable Development Plan and Budget for such Licensed Product. From the Effective Date and so long as Warner is responsible for all such Development Costs, Warner shall pay all such Development Costs paid to Third Parties, and Onyx shall invoice Warner for Onyx's internal Development Costs for Local/Regional ONYX-015 and Systemic ONYX-015 in arrears, to be paid by Warner within [ * ] days of the date of such invoice.
(ii) After Warner has satisfied its obligations under the previous paragraph, Warner shall bear 75% and Onyx shall bear 25% of all subsequent Development Costs for Local/Regional ONYX-015 and Systemic ONYX-015, subject to Section 7.3(b). In the case of the Pro-Drug Product and the Gene Product, Warner shall bear 75% and Onyx shall bear 25% of all Development Costs incurred after the time of designation of such Licensed Products for Development under Section 3.6. Notwithstanding the foregoing, Warner shall be responsible [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. for all Development Costs incurred with respect to Development activities undertaken solely to comply with the regulatory requirements of one or more jurisdictions outside the Shared Territory and which are not used to establish the efficacy of a Licensed Product as part of a Drug Approval Application in the Shared Territory. The submission of data to regulatory authorities in the Shared Territory of data generated for the sole purpose of jurisdictions outside of the Shared Territory, for the purpose of demonstrating the safety of the Licensed Products rather than obtaining efficacy approvals in the Shared Territory, shall not cause the costs of generating such data to become Development Costs.
Allocation of Development Costs. (a) Subject to Sections 5.7.2(c), 5.7.2(d), 5.7.2(e), 5.7.2(f) and 5.7.2(f), Xxxxxxxxx shall be responsible for paying [**] of the Shared Development Costs, and AstraZeneca shall be responsible for paying [**] of the Shared Development Costs.
(b) [**].
(c) Xxxxxxxxx shall be responsible for (i) the First RCC Phase III Costs; (ii) the [**] of the costs of the Additional RCC Phase III Costs; and (iii) [**] of the Additional RCC' Phase III Costs provided always that: (aa) AstraZeneca shall track and calculate all such Additional RCC Phase III Costs incurred by it which shall be determined in accordance with IFRS and AstraZeneca shall keep a complete and accurate record of all such costs; (bb) within thirty (30) days after the end of each Calendar Quarter, AstraZenec a shall submit to Xxxxxxxxx a report setting forth in reasonable detail the Additional RCC Phase III Costs incurred by it during such Calendar Quarter, with an allocation of such costs between the Parties consistent with Articles 5.7.2(c) and 5.7.2(d) (hereafter, “Quarterly Cost Report”), along with such supporting documentation as Xxxxxxxxx may reasonably request. The Quarterly Cost Report shall include the latest estimates of development budget spending for the Additional RCC Registrational Trial based on the spend to date including analysis of actual spend and projected remaining amounts to be spent under such trial; (cc) Xxxxxxxxx shall reimburse AstraZeneca for Xxxxxxxxx'x allocation of the Additional RCC Phase III Costs within 30 days of receiving the Quarterly Cost Report; and (dd) AstraZeneca shall provide Xxxxxxxxx with such appropriate documentation to support the Quarterly Cost Report upon reasonable request from Xxxxxxxxx. although any such request by Xxxxxxxxx for additional documentation shall not delay or postpone Xxxxxxxxx'x obligation under (cc) to reimburse AstraZeneca within 30 days of receiving the Quarterly Cost Report.
(d) AstraZeneca shall be responsible for the [**] of the Additional RCC Phase III Costs referenced in Section 5.7.2(c). (e)[**] [**]
Allocation of Development Costs. Subject to this Section 3.7 and Sections 7.3.4 and 7.8.2 and the other terms and conditions of this Agreement, the Development Costs incurred by either Party after the Execution Date, in accordance with the applicable Global Development Plan and Budget and Annual Development Plan and Budget, or by Medarex prior to the Execution Date as Previously Disclosed, with respect to each Product for an Indication shall be borne by the Parties such that:
Allocation of Development Costs
